The stock of Astrazeneca plc ADR (NASDAQ:AZN) last traded at $63.83, down -0.92% from the previous session.
Data from the available sources indicates that Astrazeneca plc ADR (NASDAQ:AZN) is covered by 31 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $106.75 and a low of $63.00, we find $81.61. Given the previous closing price of $64.42, this indicates a potential upside of 26.68 percent. AZN stock price is now -6.04% away from the 50-day moving average and -8.19% away from the 200-day moving average. The market capitalization of the company currently stands at $197.86B.
In total, 4 analysts have assigned it a hold rating, and 25 have given it a buy rating. Brokers who have rated the stock have averaged $82.98 as their price target over the next twelve months.
With the price target enhanced from $66.50 to $80, Jefferies Upgraded its rating from Hold to Buy for Astrazeneca plc ADR (NASDAQ: AZN).
A total of 0.05% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AZN stock. A new stake in Astrazeneca plc ADR shares was purchased by SOFINNOVA INVESTMENTS, INC. during the first quarter worth $108,353,000. FOLKETRYGDFONDET invested $26,062,000 in shares of AZN during the first quarter. In the first quarter, BALYASNY ASSET MANAGEMENT L.P. acquired a new stake in Astrazeneca plc ADR valued at approximately $19,288,000. JANNEY MONTGOMERY SCOTT LLC acquired a new stake in AZN for approximately $13,178,000. MML INVESTORS SERVICES, LLC purchased a new stake in AZN valued at around $11,176,000 in the second quarter. In total, there are 1,297 active investors with 15.98% ownership of the company’s stock.
With an opening price of $63.92 on Friday morning, Astrazeneca plc ADR (NASDAQ: AZN) set off the trading day. During the past 12 months, Astrazeneca plc ADR has had a low of $53.52 and a high of $76.56. As of last week, the company has a debt-to-equity ratio of 0.80, a current ratio of 0.87, and a quick ratio of 0.67. According to the stock market information, the enterprise value for the company is $220.20B, which is based on a 32.29 price-to-earnings ratio, a 2.41 price-to-earnings-growth ratio, and a beta of 0.51. The fifty day moving average price for AZN is $67.80 and a two-hundred day moving average price translates $69.49 for the stock.
The latest earnings results from Astrazeneca plc ADR (NASDAQ: AZN) was released for Jun, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.08, beating analysts’ expectations of $0.95 by 0.13. This compares to $0.12 EPS in the same period last year. The net profit margin was 13.85% and return on equity was 16.81% for AZN. The company reported revenue of $11.42 billion for the quarter, compared to $10.77 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.99 percent. For the current quarter, analysts expect AZN to generate $11.66B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 09/11/2023. Investors who held shares on 08/11/2023 were paid a $0.465 dividend. On an annualized basis, this represents a $1.53 dividend and a 2.39% percent yield. There was an ex-dividend date of 08/10/2023 for this dividend. In terms of dividend payout ratio, AZN is presently at 133.71%.
Astrazeneca plc ADR(AZN) Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
